Publications by authors named "Matthew Brack"
A systematic review (SR) of published efficacy studies in visceral leishmaniasis (VL) was undertaken to describe methodological aspects of design, conduct, analysis, and reporting. Studies published during 2000-2021 and indexed in the Infectious Diseases Data Observatory VL library of clinical studies were eligible for inclusion (N = 89 studies). Of the 89 studies, 40 (44.
View Article and Find Full Text PDFBackground: Occurrences of relapse after 6-months post-treatment has been reported in recent Visceral Leishmaniasis (VL) efficacy studies. A meta-analysis was carried out to quantify the proportion of relapses observed at and beyond 6-months using the Infectious Diseases Data Observatory (IDDO) systematic review (SR) database.
Methods: Studies in the IDDO SR database (1983-2021; 160 studies) were eligible for inclusion if follow-up was at least 6-months, relapse was clearly reported, and patients with HIV coinfections were excluded.
Article Synopsis
- - Lymphatic filariasis (LF) is a serious neglected tropical disease with ongoing global efforts to eliminate it as a public health problem, yet nearly 900 million people still need treatment despite over 9 billion treatments distributed since 2000.
- - A systematic literature review was conducted to gather individual participant data (IPD) related to LF treatment effectiveness and morbidity management by analyzing studies from various databases between 2000 and 2023.
- - From 138 eligible studies across 23 countries, researchers identified nearly 15,000 IPD related to infection indicators and approximately 6,100 IPD concerning clinical morbidity, revealing significant gaps in understanding treatment responses.
Article Synopsis
- * This initiative encourages data-sharing and collaborative analysis to build strong evidence on the effectiveness and safety of treatments for these diseases.
- * A Research Agenda has been developed to engage researchers and highlight important questions, with an emphasis on ethical data sharing as a means to help eliminate NTDs in the future.
Background: Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported serious adverse events (SAEs).
Methods: For this updated systematic review, we searched the following databases from 1st Jan 2016 through 2nd of May 2019: PUBMED, Embase, Scopus, Web of Science, Cochrane, clinicaltrials.
Since the coronavirus disease 2019 (COVID-19) outbreak was first reported in December 2019, many independent trials have been planned that aim to answer similar questions. Tools allowing researchers to review studies already underway can facilitate collaboration, cooperation and harmonisation. The Infectious Diseases Data Observatory (IDDO) has undertaken a living systematic review (LSR) to provide an open, accessible and frequently updated resource summarising characteristics of COVID-19 study registrations.
View Article and Find Full Text PDF